Re: Lars Budäus, Sami-Ramzi Leyh-Bannurah, Georg Salomon, et al. Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016;69:393–6

European Urology

Volumn 70, Issue 2, 2016, Pages e37-e38

  Derlin, Thorsten ^a   Eiber, Matthias ^b   Schwaiger, Markus ^b   Bengel, Frank M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIUM 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; TRACER; UNCLASSIFIED DRUG; EDETIC ACID; GLU-NH-CO-NH-LYS-(AHX)-((68)GA(HBED-CC)); OLIGOPEPTIDE;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; HIGH RISK PATIENT; HUMAN; LETTER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MOLECULAR IMAGING; NONHUMAN; PELVIS LYMPH NODE; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOCHEMISTRY; SELECTION BIAS; ANALOGS AND DERIVATIVES; MALE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSTATE TUMOR;

EDETIC ACID; HUMANS; MALE; OLIGOPEPTIDES; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84938702838     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.07.055     Document Type: Letter

References (5)

1. 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69 (2016), 393–396.
2. [2] Herrmann, K., Bluemel, C., Weineisen, M., et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56 (2015), 855–861.
3. [3] Eiber, M., Maurer, T., Souvatzoglou, M., et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56 (2015), 668–674.
4. [4] Ceci, F., Uprimny, C., Nilica, B., et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. Eur J Nucl Med Mol Imaging 42 (2015), 1284–1294.
5. [5] Afshar-Oromieh, A., Malcher, A., Eder, M., et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40 (2013), 486–495.